Posted by JIC Venture Growth Investments (VGI) announced that it has invested in Beren Therapeutics P.B.C. (“Beren Therapeutics”).
Beren Therapeutics is developing a pipeline of cyclodextrin-based therapeutics, leveraging the unique ring-shaped structure of these oligosaccharides to selectively encapsulate pathogenic compounds. Beren is initially targeting the abnormal accumulation of cholesterol within cells because it plays a pathogenic role in a broad range of diseases. Its lead candidate, adrabetadex has been recently found to show a substantial survival benefit in the treatment of individuals with infantile-onset Niemann-Pick disease type C (NPC) by the American Neurological Association.
Read more: